ARTICLE SUMMARY:
After several promising, but ultimately disappointing quarters, the US public market for medtech companies sprang back to life in Q2 and the prospects for continued activity appear strong. All the while, M&A remains stable with a returning influx of financial players.
For the past couple of years, the idea of a US public market for medtech and diagnostic companies has been an unrealized hope. Despite quarter after quarter of promising signs, the US IPO window remained basically closed to device and diagnostic companies.
